Dr. Kishore Kumar Kota

OP Timings:

Qualifications:

• Observership in CAR T-cell Therapy (May 2024): Tata Memorial Hospital, Mumbai (Under Dr. Hashmukh Jain) 

• D.M. Medical Oncology (2018 - 2021) – Tata Memorial Hospital, Mumbai, Maharashtra

• M.D. Radiation Oncology: Nizams Institute of Medical Sciences, Hyderabad, Telangana  (2015 – 2018)

• Graduated MBBS from Rangaraya Medical College, Kakinada, Andhra Pradesh (2005 – 2011)

• Graduated Secondary school from Abhyudaya High School, Bobbili, Vizianagaram, Andhra Pradesh

Work Experience:

• Currently working as a Consultant Medical and Hemato-Oncologist and teaching faculty in Mahatma Gandhi Cancer Hospital, Vishakapatnam ( Have 2 DNB seats ) since 2022

• Ad hoc Assistant Professor Medical Oncology, TMH Mumbai – HBCH RC Muzaffarpur.

Areas of interest:

• CAR T-cell therapy 
• Bone marrow transplantation
• Chemotherapy, Immunotherapy, Targeted therapy, Palliative and supportive care. 
• Hematolymphoid Malignancies: ALL, AML, Lymphoma, CLL, CML, MPN, MDS 
• Solid Malignancies: Breast, Gynaecology, Gastroenterology, Thoracic, Urology, Head & Neck, Bone and Soft Tissue, CNS 
• Special Interest: CAR T-cell therapy, Lymphoma, Germcell Tumors, Lung cancer 

Certification & Membership:

• Andhra Pradesh Medical Council registration number: 71731 

• Registered with Maharashtra State Medical Council.

• Member of the Review committee in the CRST journal

• Member of the Quality Council of India

Achievements:

• Setting up and Handling alone Medical oncology department including  OPD, general and private day care, inpatient wards at HomiBhabha cancer hospital and research centre, Muzaffarpur, Bihar (A unit of TMH, Mumbai)

Peer Reviewed Many Articles in Journals:

• Cancer Research Statistics and Treatment

Publications:

• Evaluation of Metronomic Therapy as a Low-Cost, Sustainable, Standard-of-Care Option in Desmoid Fibromatosis: Real-World Data From a Tertiary Care Center in India _ Jyoti Bajpai, MD, DM1 ; Pritesh Munot, MD, DM1 ; Kishore Kota, MD, DM1 ; Gaurav Gupta, MD, DM1 ; Kunal Gala, DNB1 ; Aashish Gulia, MCh1 ; Bharat Rekhi, MD1 ; Nehal Khanna, MD1 ; Nitin Shetty, MD1 ; Prabhat Bhargava, DM1 ; Sujay Srinivas, DM1 ; Vikas Ostwal, DM1 ; Vijay Patil, DM1 ; Vanita Noronha, DM1 ; Suyash Kulkarni, MD1 ; Siddharth Laskar, MD1 ; Kumar Prabhash, DM1 ; Girish Chinnaswamy, DM1 ; Sudeep Gupta, DM1 ; and Shripad Banavali, M
• Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation—a phase 3 study _ Amit Joshi1,†, Vijay Maruti Patil1,†, Vanita Noronha1,†, Atanu Bhattacharjee2, Nandini Menon1, Amit Kumar1,†, Parmanand Jain3, Sadaf Mukadam1, Avadhoot Shrinivas1, Anjali Punia1, Anuja Abhyankar1, Amit Agarwal1, Satvik Khaddar1, Anu Rajpurohit1, Kanteti Aditya Pavan Kumar1, Rahul Ravind1, Kishore Das1, Vikas Talreja1, Sachin Dhumal1 and Kumar Prabhash1
• COVID-19 vaccine uptake and vaccine hesitancy in Indian patients with cancer: A questionnaire-based survey _ Vanita Noronha1, George Abraham1, Suresh Kumar Bondili1, Annu Rajpurohit1, Rakesh P Menon1, Shreya Gattani1, Mehak Trikha1, Rajanigandha Tudu1, Kishore Kumar Kota1, Ajay Kumar Singh1, Prahalad Elamarthi1, Goutam Santosh Panda1, Rahul Kumar Rai1, Madala Ravi Krishna1, Sravan Kumar Chinthala1, Minit Jalan Shah1, Devanshee Shah1, Atul Tiwari1, Deep Nareshbhai Vora1, Arnav Hemant Tongaonkar1, George John1, Akshay Patil2, Nandini Sharrel Menon1, Vijay Maruti Patil1, Amit Joshi1, Shripad Banavali1, Rajendra A Badwe3, Kumar Prabhash1